EUVIMEDEUVIMED entdecken
Crossref

Metformin sensitizes non-small cell lung cancer to CDK4/6 inhibitor treatment by reducing lysosomal trapping

Yaqi Liu, Yalei Wang, Ni Zhang, Haijuan Xiong, Lipan Zhao, Ying Qi, Jiping Xie, Xiaofeng Duan, Dongsheng Yue, Shuo Qie

Science China Life Sciences · 2026

DOI: 10.1007/s11427-024-3015-1 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science China Life Sciences, 2026. Verfasst von Yaqi Liu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, China. Hauptthemen laut MEDLINE: Metformin, Cyclin-Dependent Kinase 4, Carcinoma, Non-Small-Cell Lung, Lysosomes. Die Arbeit nennt 72 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The hyperactivation of cyclin D1-CDK4/6 signaling is correlated with tumour metastasis and poor prognosis in patients with non-small cell lung cancer (NSCLC), suggesting the therapeutic potential of targeting CDK4/6 to treat NSCLC. Our preliminary data indicate CDK4/6 inhibitors are sequestered in lysosomes in NSCLC cells, a phenomenon that is termed lysosomal trapping and is associated with intrinsic drug resistance. It is promising to search for new compounds that could be co-administered with CDK4/6 inhibitors to reduce lysosomal trapping, thereby enhancing the sensitivity of NSCLC cells. Here, we find that metformin reduces the activity of the lysosomal pathway through genome-wide analyses; consistently, metformin reduces lysosomal trapping of CDK4/6 inhibitors in NSCLC cells. Biologically, metformin enhances the suppressive effects of CDK4/6 inhibitors on cell cycle progression, cell proliferation, and colony formation. Mechanistically, metformin suppresses lysosomal trapping by: (i) reducing translocation of TFEB into nuclei that leads to decreased lysosome biogenesis and (ii) disrupting lysosomal acidic environment through reduced V-ATPase activity and decreased interaction between LAMP1/LAMP2 and TMEM175. Clinically, combined treatment with metformin and CDK4/6 inhibitors decreased the growth of mouse xenografts and tumour cell organoids. In conclusion, our study provides a new mechanism for utilizing metformin to treat NSCLC by reducing lysosomal trapping, thereby increasing cellular sensitivity to CDK4/6 inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MetforminCyclin-Dependent Kinase 4Carcinoma, Non-Small-Cell LungLysosomesLung NeoplasmsCyclin-Dependent Kinase 6Protein Kinase InhibitorsHumansAnimalsCell Line, TumorMiceCell ProliferationXenograft Model Antitumor AssaysMice, NudeDrug SynergismBasic Helix-Loop-Helix Leucine Zipper Transcription FactorsDrug Resistance, Neoplasm

Stichwörter der Autor:innen

CDK4/6 inhibitorslysosomal trappingmetforminnon-small cell lung cancertherapeutic efficacy

Substanzen

MetforminCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6CDK4 protein, humanProtein Kinase InhibitorsCDK6 protein, humanBasic Helix-Loop-Helix Leucine Zipper Transcription FactorsTFEB protein, human

Autor:innen und Institutionen

  • Department of Pathology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, China.
  • National Clinical Research Center for Cancer, Tianjin, 300060, China.
  • Key Laboratory of Cancer Prevention and Therapy (Tianjin), Tianjin, 300060, China.
  • Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, China.
  • Department of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, China.
  • Tianjin Lung Cancer Center, Tianjin, 300060, China.

Zitieren

APA

Liu, Y., Wang, Y., Zhang, N., Xiong, H., Zhao, L., Qi, Y., Xie, J., Duan, X., Yue, D., & Qie, S. (2026). Metformin sensitizes non-small cell lung cancer to CDK4/6 inhibitor treatment by reducing lysosomal trapping. Science China Life Sciences. https://doi.org/10.1007/s11427-024-3015-1

Vancouver

Liu Y, Wang Y, Zhang N, Xiong H, Zhao L, Qi Y, et al. Metformin sensitizes non-small cell lung cancer to CDK4/6 inhibitor treatment by reducing lysosomal trapping. Science China Life Sciences. 2026. doi:10.1007/s11427-024-3015-1

BibTeX
@article{Liu2026,
  author = {Liu, Yaqi and Wang, Yalei and Zhang, Ni and Xiong, Haijuan and Zhao, Lipan and Qi, Ying and Xie, Jiping and Duan, Xiaofeng and Yue, Dongsheng and Qie, Shuo},
  title = {Metformin sensitizes non-small cell lung cancer to CDK4/6 inhibitor treatment by reducing lysosomal trapping},
  journal = {Science China Life Sciences},
  year = {2026},
  doi = {10.1007/s11427-024-3015-1}
}
Kostenlos starten →